Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181893 · ClinicalTrials.gov registry record · Phase 2
A Study In Adults With Moderate To Severe Dermatomyositis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03181893: Completed Phase 2 study, sponsored by Pfizer.
NCT03181893 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181893, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
Primary Outcome
The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12. The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS). ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\
Interventions
- DRUG Placebo Arm
- DRUG PF-06823859 low
- DRUG PF-06823859 high
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 2 |
What the finished NCT03181893 record still lists
NCT03181893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo Arm is the first listed.
NCT03181893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03181893 about?
NCT03181893 is a clinical study titled "A Study In Adults With Moderate To Severe Dermatomyositis". A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
What is the current status of trial NCT03181893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2018-01-23. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT03181893?
The interventions under investigation include: Placebo Arm (DRUG), PF-06823859 low (DRUG), PF-06823859 high (DRUG).
Who is sponsoring clinical trial NCT03181893?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03181893's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI